I’ve spent the better part of a decade inside the belly of the beast—coordinating partnering calendars for JPM Week in San Francisco and managing the logistics for BIO International. If you’ve ever found yourself shivering on a sidewalk in Union Square trying to find an Uber, or debating whether a 30-minute meeting at the InterContinental is worth the walk from the Moscone Center, you know the drill: not all events are created equal.
Recently, I’ve been getting hit AACR 2026 San Diego venue with questions about the THMA Pharmacy Growth Collaborative. Specifically, decision-makers in the pharma and biotech space want to know: is this a legitimate venue for high-level 340B strategy, or is it just another networking mixer masquerading as a business development opportunity? Let’s strip away the marketing fluff and look at the actual ROI of your time.
The 340B Strategy Forum Reality Check
When we talk about a 340B strategy forum, we aren't talking about "networking." We are talking about compliance, formulary governance, and the razor-thin margins of ambulatory infusion access. If you are a commercial leader or a head of market access, you don't need a keynote speaker telling you that the 340B landscape is "evolving." You need to know how to navigate the current contracting environment.
Is THMA the place for that? It depends on your objective. If your goal is to understand the tactical shifts in formulary governance, this collaborative offers a unique, if dense, environment. However, many of these "collaboratives" suffer from a lack of high-level regulatory decision-makers. You’ll find plenty of mid-level consultants, but if you’re looking to break through to the people who influence major hospital network decisions, you might find the volume of "badge scanners"—people there just to harvest leads—outweighs the substantive strategic partners.
Opportunity Cost: JPM Week vs. Specialized Collaboratives
If you have a limited travel budget, you are likely choosing between massive events like those run by Informa Connect or more specialized, smaller-scale forums. Let’s be blunt: JPM Week is for capital formation and investor visibility. If you aren't actively raising a Series B or preparing for an exit, the opportunity cost of being in San Francisco in January is astronomical. You are paying thousands for flights and hotels just to stand in a hotel lobby near Union Square where your probability of a meaningful 340B strategy discussion is near zero.
In contrast, Demy-Colton manages events that are structurally different. They focus on the high-intent partnering process. When I evaluate a conference, I look at the floor plan and the neighborhood. An event in a sprawling convention center is a time-waster; an event in a self-contained hotel venue that forces interaction—that is where the 1:1 meetings actually happen.
ROI Comparison Table
Event Type Primary Function 340B Strategy Value Efficiency Rating JPM Week Capital/Investors Low Low (Logistics nightmare) Formal Partnering (e.g., BIO) BD/Commercial Medium High (Structured) THMA/Collaboratives Niche Governance High (Targeted) Medium (Variable quality)The Tech Stack: Genomics, Multiomics, and Data Harvesting
One trend I’ve noticed across these forums is the intersection of genomics and multiomics technology with pharmacy access. If you are working in specialty pharmacy, the data streams surrounding patient outcomes in multiomics are becoming the backbone of value-based contracting. If your strategy forum isn't addressing the technical integration of this data, you are looking at yesterday's playbook.
From a digital marketing and BD perspective, keep an eye on how these platforms track your interest. When you sign up for these forums, you are entering a digital ecosystem. You’ll notice the ubiquitous CookieYes consent banner on their registration pages. That isn't just for GDPR compliance; it’s the gateway to behavioral tracking.
More specifically, look at the Cloudflare Bot Management cookies being dropped on your browser—the __cf_bm, __cfruid, and _cfuvid markers. These are used to ensure the platform isn't being scraped by competitors, but they also track your navigation patterns within the portal. If you are spending 40 minutes on the "Ambulatory Infusion Access" speaker list, the platform knows. Use this to your advantage: if you’re an organizer or a high-level delegate, these analytics tell you exactly which topics move the needle for your audience.
Why PartneringONE Remains the Gold Standard
I am frequently asked why some events feel "loose" and others feel like a business machine. The answer is usually the software stack. If an event uses partneringONE, they are inherently shifting the event toward a structured outcome. PartneringONE allows you to filter participants by their functional role—specifically targeting folks in formulary governance rather than just anyone who can afford a badge.
If you attend a forum that relies on a clunky, proprietary spreadsheet-based system, leave. It’s a waste of time. The efficiency of a partnering tool is the single best predictor of whether you will actually walk away with a signed deal or a stack of useless business cards.
Who Should Attend THMA?
I’ve categorized the utility of these collaborative-style forums based on business function:
- Market Access Teams: Highly useful. If the agenda covers 340B compliance and state-level policy, you will find peers who are dealing with the exact same regulatory headaches. Genomics/Multiomics Startups: Use caution. Unless there is a dedicated track for clinical adoption and pharmacy integration, you might be preaching to the choir instead of finding buyers. Sales/Commercial Managers: Approach with skepticism. If you are there to hunt for "leads" rather than contribute to the 340B strategy discussion, you will find the return on your time—and the cost of the event—to be deeply underwhelming.
The "Events That Waste Time" List
In my line of work, I keep a private "blacklist" of events that look great on a brochure but are disasters in practice. Avoid any event that:
Promotes "networking" as the primary value proposition without providing a pre-scheduled 1:1 meeting module. Takes place in a venue where the sessions are in one building and the networking is in a hotel three miles away (the "commuter trap"). Focuses on "innovation" in the 340B space without inviting actual hospital pharmacy directors to the table.
Final Verdict
The THMA Pharmacy Growth Collaborative can be a high-value environment if your 340B strategy is currently stalled by a lack of peer-to-peer benchmarking. It is not, however, a substitute for a structured partnering event. If you need capital, stick to the heavy hitters. If you need to solve specific problems regarding ambulatory infusion access or pharmacy compliance, these smaller collaboratives are where the rubber meets the road.
Just remember: when you sign up, check the privacy policy, clear your cf_clearance cookies if you want to keep your digital intent private, and for the love of everything, don't let a "badge scan" define your success. Focus on the people sitting in the back of the room during the technical sessions—they are usually the ones actually doing the work.
Need help auditing your current conference calendar? Stop relying on generic "get out there more" advice. Map your conference schedule to your actual Q3 and Q4 commercial goals. If the event doesn't facilitate a 1:1, it isn't a conference; it’s an expensive vacation.